Abstract
The innominate artery is a predilection site for atherosclerotic lesion formation in hyperlipidemic mice. The lesions at this site in chow-fed apo E-/- mice progress from fatty streaks through stages that include atheroma with large necrotic areas, fibro-fatty nodules containing chondrocyte-like cells and highly calcified, acellular plaques. The advanced lesions in the innominate arteries of the apo E-/- mice exhibit a reproducible frequency of intra-plaque hemorrhage that occurs primarily as a result of fissures through lateral fatty streaks that form adjacent to or on top of the established plaques. However, this plaque disruption is not equivalent to plaque rupture in human lesions where there is rupture of well formed fibrous caps. The plaque disruption in the lesions of the chow-fed apo E-/- mice also do not lead to formation of occlusive thrombi, the predominant marker of plaque rupture in humans. Thus, although the lesions in the innominate arteries of hyperlipidemic mice progress to very advanced stages of the disease, they are not, in our opinion a model in which to study the mechanisms of plaque rupture in humans. The advanced lesions in the innominate arteries of the apo E-/- mice may however be adequate models for studying vascular fibrosis and calcification.
Current Drug Targets
Title: Progression and Disruption of Advanced Atherosclerotic Plaques in Murine Models
Volume: 9 Issue: 3
Author(s): Michael E. Rosenfeld, Michelle M. Averill, Brian J. Bennett and Stephen M. Schwartz
Affiliation:
Abstract: The innominate artery is a predilection site for atherosclerotic lesion formation in hyperlipidemic mice. The lesions at this site in chow-fed apo E-/- mice progress from fatty streaks through stages that include atheroma with large necrotic areas, fibro-fatty nodules containing chondrocyte-like cells and highly calcified, acellular plaques. The advanced lesions in the innominate arteries of the apo E-/- mice exhibit a reproducible frequency of intra-plaque hemorrhage that occurs primarily as a result of fissures through lateral fatty streaks that form adjacent to or on top of the established plaques. However, this plaque disruption is not equivalent to plaque rupture in human lesions where there is rupture of well formed fibrous caps. The plaque disruption in the lesions of the chow-fed apo E-/- mice also do not lead to formation of occlusive thrombi, the predominant marker of plaque rupture in humans. Thus, although the lesions in the innominate arteries of hyperlipidemic mice progress to very advanced stages of the disease, they are not, in our opinion a model in which to study the mechanisms of plaque rupture in humans. The advanced lesions in the innominate arteries of the apo E-/- mice may however be adequate models for studying vascular fibrosis and calcification.
Export Options
About this article
Cite this article as:
Rosenfeld E. Michael, Averill M. Michelle, Bennett J. Brian and Schwartz M. Stephen, Progression and Disruption of Advanced Atherosclerotic Plaques in Murine Models, Current Drug Targets 2008; 9 (3) . https://dx.doi.org/10.2174/138945008783755575
DOI https://dx.doi.org/10.2174/138945008783755575 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recombinant Tissue-Type Plasminogen Activator (Alteplase) in the Management of Acute Ischemic Stroke: A Review of its Pharmacological Properties, Efficacy, Safety and Pharmacoeconomic Aspects
Current Drug Therapy Anti-inflammatory strategies in stroke: a potential therapeutic target
Current Vascular Pharmacology High-pitch Dual-source CT Angiography before TAVI - the Value of ECG Gating
Current Medical Imaging Implantable Medical Devices and Tissue Engineering: An Overview of Manufacturing Processes and the Use of Polymeric Matrices for Manufacturing and Coating their Surfaces
Current Medicinal Chemistry CypA: A Potential Target of Tumor Radiotherapy and/or Chemotherapy
Current Medicinal Chemistry Current Theories and Clinical Trial Evidence for Limiting Human Abdominal Aortic Aneurysm Growth
Current Drug Targets The GH/IGF-1 Axis in Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Three-dimensional Printing-Driving Liver Therapies
Current Medicinal Chemistry Molecular Targets in Osteoarthritis: Metalloproteinases and Their Inhibitors
Current Drug Targets Closure of Patent Foramen Ovale: When and How?
Current Vascular Pharmacology 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry Use of Diffusion-Weighted Magnetic Resonance Imaging and Apparent Diffusion Coefficient in Gastric Cancer Staging
Current Medical Imaging An Update on Autoinflammatory Diseases
Current Medicinal Chemistry Kinin Receptors in Vascular Biology and Pathology
Current Vascular Pharmacology Potential Interactions of Carotenoids with Other Bioactive Food Components in the Prevention of Chronic Diseases
Current Bioactive Compounds Treatment Strategies of Age-Related Memory Dysfunction by Modulation of Neuronal Plasticity
Mini-Reviews in Medicinal Chemistry Microbleeds after Stent-assisted Coil Embolization of Unruptured Intracranial Aneurysms: Incidence, Risk Factors and the Role of Thromboelastography
Current Neurovascular Research TGF Beta Inhibition for Cancer Therapy
Current Cancer Drug Targets Osteoprotegerin and Diabetes-Associated Pathologies
Current Molecular Medicine From Diabetes to Metabolic Syndrome: A View Point on An Evolving Concept
Current Pharmaceutical Design